This transition of SCLC to a non-neuroendocrine/mesenchymal state demonstrates a more pronounced response to ICB and overall better survival, with tumours more infiltrated by CD45+/PD-L1+ immune cells and CD3+ T cells. The gene discussed is PTPRC; the disease is neoplasm.